



27 July 2017

Sydney, Australia

## ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

### Registered Office:

Suite 1 Level 6  
50 Queen St  
Melbourne VIC 3000  
Australia

### Operations Office:

Suite 3 Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

### Board of Directors

#### Mr Peter Marks

Chairman  
Non-Executive  
Director

#### Dr Graham Kelly

Chief Executive Officer  
Managing Director

#### Dr Ian Dixon

Non-Executive  
Director

## NOXOPHARM LIMITED RESEARCH REPORT PREPARED BY APP SECURITIES

Noxopharm Limited ( ASX Code: NOX) advises that an updated research report on the Company has been released by APP Securities Pty Ltd.

A copy of the report will be placed on the Noxopharm website today, at:

<http://www.noxopharm.com/irm/content/analyst-reports.aspx?RID=423>

APP Securities has been retained by Noxopharm to provide this report.

Russell Wright, the analyst responsible for writing this report, does not receive any direct benefits or assistance from Noxopharm. Disclosures relating to shares owned by the analyst can be found on Page 8 of the report.

For further information, please contact:

#### Investor & Corporate Enquiries:

Prue Kelly  
M: 0459 022 445  
info@noxopharm.com

[www.noxopharm.com](http://www.noxopharm.com)

#### Company Secretary :

David Franks  
T: +61 2 9299 9690  
E: dfranks@fa.com.au

### About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney, Melbourne and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of resistance in cancer cells to radiotherapy and chemotherapy, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates including idronoxil-C under development. The Company also has an expanding pipeline of non-oncology drugs.

## **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.